Новые аспекты хондропротекциипри остром и хроническом суставном синдроме
Новые аспекты хондропротекциипри остром и хроническом суставном синдроме
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Berenbaum F. Osteoarthritis: Preface. Best Pract Res Clin Rheumatol 2010; 24: 1–2.
2. Anandarajah A. Erosive osteoarthritis. Discov Med 2010; 9: 468–77.
3. Berenbaum F. Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation. Joint Bone Spine 2000; 67: 561–4.
4. Martel-Pelletier J, McCollum R, Fujimoto N et al. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807–15.
5. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151–60.
6. Clark AG, Jordan JM, Vilim V et al. Serum cartilage oligomeric matrix protein reflects 28 IJCP Supplement 128 July 2002 osteoarthritis presence and severity. Arthritis Rheum 1999; 42: 2356–64.
7. Kunitomo T, Takahashi KA, Arai Y et al. Influence of extracellular matrix on the expression of inflammatory cytokines, proteases, and apoptosis-related genes induced by hydrostatic pressure in three-dimensionally cultured chondrocytes. J Orthop Sci 2009; 14: 776–83.
8. Vilim V, Vytasck R, Vencovsky J et al. The effect of synovitis on COMP levels in sera of patients with osteoarthrosis. Trans Orthop Res Soc 1999; 24: 441–5.
9. Petersson IF, Boegard T, Svensson B et al. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998; 37: 46–50.
10. Bennett A. Nimesulide: a well-established cyclooxygenase-2 inhibitor with many other pharmacological propertes relevant to inflammatory diseases. In: Vane JJ, Botting RM eds. Therapeutic Roles of Selective COX-2 Inhibitors. London: William Harvey Press 2001; 524–40.
11. Rainsford KD. The discovery, development and novel actions of nimesulide. In: Rainsford KD, ed. Nimesulide, Actions and Uses. Basel, Boston, Berlin: Birkhauser Verlag, 2005.
12. Rainsford KD. members of the consensus Report Group inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
13. Ostalowska A, Birkner E, Wiecha M et al. Lipid peroxidation and antioxidant enzymes in synovial fluid of patients with primary and secondary osteoarthritis of the knee joint. Osteoarthr Cartil 2006; 14: 139–45.
14. Sutipornpalangkul W, Morales N. Lipid peroxidation, glutathione, vitamin E, and antioxidant enzymes in synovial fluid from patients with osteoarthritis. Int J Rheum Dis 2009; 12: 324–8.
15. Sutipornpalangkul W, Morales NP, Harnroongroj T. Free radicals in primary knee osteoarthritis. J Med Assoc Thai 2009; 92: 268–74.
16. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Alt Med Rev 1997; 2: 155–76.
17. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010; 1192: 230–7.
18. Егоров И.В., Цурко В.В. Формы воспалительных реакций: единство противоположностей. Практикующий врач. 2010; 1: 3–8.
19. Popa-Nita O, Rollet-Labelle E, Thibault N et al. Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase. J Leukoc Biol 2007; 82 (3): 763–73.
20. Хитрик Н.М., Дидковский Н.А., Малашенкова И.К. и др. Бактерицидная и поглотительная функция нейтрофилов при подагре. Тер. арх. 2009; 10: 49–52.
21. So A. New knowledge on the pathophysiology and therapy of gout. Z Rheumatol 2007; 66: 564–7.
22. Pascual E, Pedraz T. Gout. Curr Opin Rheumatol 2004; 16: 282–6.
23. Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611–6.
24. Padang C, Muirden KD, Schumacher HR. Chronic tophaceous gout in the northern part of Sulawesi. Proceeding of the eight APLAR Congress of Rheumatology. Melbourne, 1996.
25. Schweyer S, Hemmerlein B, Radzun HJ. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows Arch 2000; 437: 534–9.
26. Nishida Y, Kamatani N, Miyamoto T. Above-normal concentrations of lipid peroxide in serum of patients with gout. Clin Chem 1984; 30: 592–3.
27. Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005; 44 (9): 1090–6.
28. Егоров И.В., Хитрик Н.М., Цурко В.В. Функциональное состояние нейтрофилов у пожилых больных хроническим подагрическим артритом в стадии обострения. Клин. геронтол. 2008; 9: 70.
29. Адейшвили-Сыромятникова М.К. Влияние лазеротерапии на регуляцию перекисных процессов в крови больных подагрой. Експериментальна і клінічна медицина. 2009; 1: 85–8.
30. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation 2002; 26: 139–42.
31. Huskinsson EC, Berry P, Gishen P. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol 1995; 22: 1941–6.
32. Егоров И.В., Цурко В.В. Суставной синдром в ревматологии: современная патогенетическая концепция и обоснование терапевтического применения нимесулида. Фарматека. 2008; 8: 37–41.
33. Barracchini A, Franceschini N, Amicosante G et al. Can Non-steroidal Anti-inflammatory Drugs Act as Metalloproteinase Modulators? An In vitro Study of inhibition of Collagenase Activity. J Pharm Pharmacol 1998; 50: 1417–23.
34. Pelletier JP, Martel-Pelietier J. Effects of Nimesulide and Naproxen on the Degradation and Metalloprotease Synthesis of Human Osteoarthritic Cartiiaqe. Drugs 1993; 46: 34–9.
35. Kullich W, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract 2002; 128: 24–30.
36. Kullich W, Fagerer N, Schwann H. Effect of the NSAID nimesulide on the radical scavenger glutathione S-transferase in patients with osteoarthritis of the knee. Cur Med Res Opin 2007; 23: 1981–6.
37. Maffei Facino R, Carini M, Aldini G et al. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneimittelforschung 1995; 45: 1102–10.
38. Maffei-Facino R, Carini M, Aldini G. Anti-oxidant activity of nimesulide and its main metabolites. Drugs 1993; 46 (Suppl. 1).
39. Bevilacqua M, Vago T, Baldi G et al. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacology 1994; 268: 415–23.
40. Zheng SX, Monithys-Mickalad A et al. In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: efects on HRP– and luminal dependent chemoluminescence produced by human chondrocytes. Osteoarthri Cartil 2000; 8 (4): 419–25.
41. Degner F, Lanes S, van Ryn J. Pharmacological and clinical profile meloхicam. Therapeutic roles of selective COХ-2 inhibitors. Ed. Vane JR, Botting RM. London: William Harvey Press, 2001.
42. Henrotin Y, Reginster T. In vitro difference among non-steroidal anti-inflammatory drug in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage 1999; 7: 355–7.
43. Pruss TP, Strossing H et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66: 18–21.
44. Егоров И.В., Цурко В.В., Леоненко И.В. и др. Внутрисуставное введение НПВП: новый этап в современной ревматологии. Клин. геронтол. 2009; 8–9: 43–7.
45. Hajjal HEL, Marcelis A, Devogelaer J-P. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheum 2003; 30: 2444–51.
46. Henrotin Y, de Laval X, Mathy-Hartet M et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 1997;
25: 314–9.
47. Gonsalez E, de la Cruz C, de Nicola's R et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994; 41: 171–8.
48. Егоров И.В. Современные подходы к антиоксидантной поддержке пациентов с сердечно-сосудистой патологией. Поликлиника. 2008; 2: 25–8.
49. Егоров И.В., Цурко В.В., Воробьев П.А. Поражение сердечно-сосудистой системы на ранней стадии подагры. Клин. геронтол. 2008; 9: 62.
2. Anandarajah A. Erosive osteoarthritis. Discov Med 2010; 9: 468–77.
3. Berenbaum F. Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation. Joint Bone Spine 2000; 67: 561–4.
4. Martel-Pelletier J, McCollum R, Fujimoto N et al. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807–15.
5. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151–60.
6. Clark AG, Jordan JM, Vilim V et al. Serum cartilage oligomeric matrix protein reflects 28 IJCP Supplement 128 July 2002 osteoarthritis presence and severity. Arthritis Rheum 1999; 42: 2356–64.
7. Kunitomo T, Takahashi KA, Arai Y et al. Influence of extracellular matrix on the expression of inflammatory cytokines, proteases, and apoptosis-related genes induced by hydrostatic pressure in three-dimensionally cultured chondrocytes. J Orthop Sci 2009; 14: 776–83.
8. Vilim V, Vytasck R, Vencovsky J et al. The effect of synovitis on COMP levels in sera of patients with osteoarthrosis. Trans Orthop Res Soc 1999; 24: 441–5.
9. Petersson IF, Boegard T, Svensson B et al. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998; 37: 46–50.
10. Bennett A. Nimesulide: a well-established cyclooxygenase-2 inhibitor with many other pharmacological propertes relevant to inflammatory diseases. In: Vane JJ, Botting RM eds. Therapeutic Roles of Selective COX-2 Inhibitors. London: William Harvey Press 2001; 524–40.
11. Rainsford KD. The discovery, development and novel actions of nimesulide. In: Rainsford KD, ed. Nimesulide, Actions and Uses. Basel, Boston, Berlin: Birkhauser Verlag, 2005.
12. Rainsford KD. members of the consensus Report Group inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
13. Ostalowska A, Birkner E, Wiecha M et al. Lipid peroxidation and antioxidant enzymes in synovial fluid of patients with primary and secondary osteoarthritis of the knee joint. Osteoarthr Cartil 2006; 14: 139–45.
14. Sutipornpalangkul W, Morales N. Lipid peroxidation, glutathione, vitamin E, and antioxidant enzymes in synovial fluid from patients with osteoarthritis. Int J Rheum Dis 2009; 12: 324–8.
15. Sutipornpalangkul W, Morales NP, Harnroongroj T. Free radicals in primary knee osteoarthritis. J Med Assoc Thai 2009; 92: 268–74.
16. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Alt Med Rev 1997; 2: 155–76.
17. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010; 1192: 230–7.
18. Егоров И.В., Цурко В.В. Формы воспалительных реакций: единство противоположностей. Практикующий врач. 2010; 1: 3–8.
19. Popa-Nita O, Rollet-Labelle E, Thibault N et al. Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase. J Leukoc Biol 2007; 82 (3): 763–73.
20. Хитрик Н.М., Дидковский Н.А., Малашенкова И.К. и др. Бактерицидная и поглотительная функция нейтрофилов при подагре. Тер. арх. 2009; 10: 49–52.
21. So A. New knowledge on the pathophysiology and therapy of gout. Z Rheumatol 2007; 66: 564–7.
22. Pascual E, Pedraz T. Gout. Curr Opin Rheumatol 2004; 16: 282–6.
23. Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611–6.
24. Padang C, Muirden KD, Schumacher HR. Chronic tophaceous gout in the northern part of Sulawesi. Proceeding of the eight APLAR Congress of Rheumatology. Melbourne, 1996.
25. Schweyer S, Hemmerlein B, Radzun HJ. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows Arch 2000; 437: 534–9.
26. Nishida Y, Kamatani N, Miyamoto T. Above-normal concentrations of lipid peroxide in serum of patients with gout. Clin Chem 1984; 30: 592–3.
27. Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005; 44 (9): 1090–6.
28. Егоров И.В., Хитрик Н.М., Цурко В.В. Функциональное состояние нейтрофилов у пожилых больных хроническим подагрическим артритом в стадии обострения. Клин. геронтол. 2008; 9: 70.
29. Адейшвили-Сыромятникова М.К. Влияние лазеротерапии на регуляцию перекисных процессов в крови больных подагрой. Експериментальна і клінічна медицина. 2009; 1: 85–8.
30. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation 2002; 26: 139–42.
31. Huskinsson EC, Berry P, Gishen P. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol 1995; 22: 1941–6.
32. Егоров И.В., Цурко В.В. Суставной синдром в ревматологии: современная патогенетическая концепция и обоснование терапевтического применения нимесулида. Фарматека. 2008; 8: 37–41.
33. Barracchini A, Franceschini N, Amicosante G et al. Can Non-steroidal Anti-inflammatory Drugs Act as Metalloproteinase Modulators? An In vitro Study of inhibition of Collagenase Activity. J Pharm Pharmacol 1998; 50: 1417–23.
34. Pelletier JP, Martel-Pelietier J. Effects of Nimesulide and Naproxen on the Degradation and Metalloprotease Synthesis of Human Osteoarthritic Cartiiaqe. Drugs 1993; 46: 34–9.
35. Kullich W, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract 2002; 128: 24–30.
36. Kullich W, Fagerer N, Schwann H. Effect of the NSAID nimesulide on the radical scavenger glutathione S-transferase in patients with osteoarthritis of the knee. Cur Med Res Opin 2007; 23: 1981–6.
37. Maffei Facino R, Carini M, Aldini G et al. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneimittelforschung 1995; 45: 1102–10.
38. Maffei-Facino R, Carini M, Aldini G. Anti-oxidant activity of nimesulide and its main metabolites. Drugs 1993; 46 (Suppl. 1).
39. Bevilacqua M, Vago T, Baldi G et al. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacology 1994; 268: 415–23.
40. Zheng SX, Monithys-Mickalad A et al. In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: efects on HRP– and luminal dependent chemoluminescence produced by human chondrocytes. Osteoarthri Cartil 2000; 8 (4): 419–25.
41. Degner F, Lanes S, van Ryn J. Pharmacological and clinical profile meloхicam. Therapeutic roles of selective COХ-2 inhibitors. Ed. Vane JR, Botting RM. London: William Harvey Press, 2001.
42. Henrotin Y, Reginster T. In vitro difference among non-steroidal anti-inflammatory drug in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage 1999; 7: 355–7.
43. Pruss TP, Strossing H et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66: 18–21.
44. Егоров И.В., Цурко В.В., Леоненко И.В. и др. Внутрисуставное введение НПВП: новый этап в современной ревматологии. Клин. геронтол. 2009; 8–9: 43–7.
45. Hajjal HEL, Marcelis A, Devogelaer J-P. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheum 2003; 30: 2444–51.
46. Henrotin Y, de Laval X, Mathy-Hartet M et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 1997;
25: 314–9.
47. Gonsalez E, de la Cruz C, de Nicola's R et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994; 41: 171–8.
48. Егоров И.В. Современные подходы к антиоксидантной поддержке пациентов с сердечно-сосудистой патологией. Поликлиника. 2008; 2: 25–8.
49. Егоров И.В., Цурко В.В., Воробьев П.А. Поражение сердечно-сосудистой системы на ранней стадии подагры. Клин. геронтол. 2008; 9: 62.
Авторы
И.В.Егоров, В.В.Цурко
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.